Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives Sell (D-) Rating from Weiss Ratings

Key Points

• Arrowhead Pharmaceuticals has retained a "sell (D-)" rating from Weiss Ratings, indicating concerns about its stock performance.
• After recently released earnings show a larger-than-expected EPS loss, analysts have mixed ratings for the company, with one upgrade to "strong-buy" and a consensus rating of "Moderate Buy."
• The stock price recently rose to $38.00, despite experiencing volatility with a 12-month high of $40.29 and a low of $9.57.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report)'s stock had its "sell (d-)" rating reiterated by equities researchers at Weiss Ratings in a report issued on Friday,Weiss Ratings reports.

Other equities research analysts have also issued research reports about the stock. Royal Bank Of Canada decreased their price objective on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a report on Friday, August 8th. B. Riley upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 11th. TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. Chardan Capital reiterated a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, August 11th. Finally, Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $43.14.

Arrowhead Pharmaceuticals Trading Up 1.7%

Shares of Arrowhead Pharmaceuticals stock traded up $0.65 during trading on Friday, hitting $38.00. The stock had a trading volume of 1,456,960 shares, compared to its average volume of 2,050,328. The firm's fifty day simple moving average is $30.24 and its 200-day simple moving average is $20.46. The stock has a market cap of $5.25 billion, a PE ratio of -29.69 and a beta of 1.13. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $40.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million for the quarter, compared to analysts' expectations of $29.01 million. During the same period in the previous year, the business earned ($1.38) EPS. As a group, sell-side analysts expect that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 20,000 shares of the business's stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total transaction of $700,000.00. Following the sale, the insider owned 212,122 shares of the company's stock, valued at approximately $7,424,270. The trade was a 8.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders have sold 60,000 shares of company stock worth $1,725,000. 4.30% of the stock is currently owned by insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Several large investors have recently bought and sold shares of ARWR. GAMMA Investing LLC grew its position in Arrowhead Pharmaceuticals by 297.6% during the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 1,628 shares during the last quarter. Virtus Advisers LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $34,000. Salomon & Ludwin LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at $34,000. Nisa Investment Advisors LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 75.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 1,308 shares during the period. Finally, CWM LLC raised its position in Arrowhead Pharmaceuticals by 134.3% during the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 2,523 shares during the period. Hedge funds and other institutional investors own 62.61% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.